U.S. — The FDA pharmacy compounding advisory committee is scheduled to convene on July 23 and July 24, 2025. The committee plans to discuss seven specific peptides: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon.

The Biden administration banned compounding pharmacies from producing 19 research peptides in 2023. At that time, the FDA cited health risks such as priapism and the potential to aid tumor growth as reasons for the prohibition.

If restrictions on these seven peptides are eased, U.S. compounding pharmacies would be able to produce and fill prescriptions for them. Peptides are defined as short-chain amino acids. The committee currently consists of three voting members, six vacant positions, and one non-voting member representing the pharmaceutical industry. The FDA is not required to follow the recommendations of its pharmacy compounding advisory committee.

Mohammed Chammout, a retail pharmacist, stated that many patients are awaiting the potential reclassification of these peptides. "There are a lot of patients who are foaming at the mouth waiting for these peptides to get moved to Category 1 legal status," Chammout said.

Conversely, Eric Topol, director and founder of the Scripps Research Translational Institute, stated that the ban is appropriate for peptides lacking sufficient safety data. "The ban is appropriate for these peptides that have no data and all sorts of concerns regarding safety," Topol said. He also commented on the influence of U.S. health secretary Robert F Kennedy Jr., stating, "Whatever RFK is pushing for will somehow get done." Kennedy, the U.S. health secretary, was involved in changes to vaccine recommendations by the federal vaccine advisory committee that were subsequently blocked by a court.

Anant Vinjamoori, chief medical officer of Hims, noted that the evidence base for these treatments is still developing. "The honest answer is that the evidence base is still developing, which is true of many treatments that are now standard of care," Vinjamoori said. He added, "What exists is largely preclinical, but preclinical evidence isn't no evidence."

Why It Matters

The upcoming meeting of the FDA pharmacy compounding advisory committee could change the availability of specific peptides from U.S. compounding pharmacies. This follows a 2023 ban by the Biden administration on 19 research peptides due to cited health risks. A decision to ease restrictions would allow these pharmacies to produce and dispense the seven peptides under discussion. The discussion involves balancing patient access and potential health concerns, a topic that has drawn differing views from healthcare professionals regarding the existing scientific evidence for these compounds.